Network pharmacology study on anti-depressant mechanism of Shuyu Capsule
Konferenz: BIBE 2019 - The Third International Conference on Biological Information and Biomedical Engineering
20.06.2019 - 22.06.2019 in Hangzhou, China
Tagungsband: BIBE 2019
Seiten: 12Sprache: EnglischTyp: PDF
Persönliche VDE-Mitglieder erhalten auf diesen Artikel 10% Rabatt
Autoren:
Li, Liting; Liu, Mimi (Guangdong Pharmaceutical University, Guangdong Guangzhou, China)
Qiu, Haiyan (Guangdong Huangcun Sports Training Center (Rehabilitation Center), Guangdong Guangzhou, China)
Cai, Yongming (Guangdong Pharmaceutical University,Guangdong Guangzhou, China & Guangdong Provincial TCM Precision Medicine Big Data Engineering Technology Research Center, Guangdong Guangzhou, China & Guangdong University College of Precision Medicine Big Data Engineering Research Center Based on Cloud Computing, Guangdong Guangzhou, China)
Inhalt:
Depression is a common emotional mental disorder with high morbidity, recurrence rate and disability rate. The incidence of depression increases year by year, reducing the quality of life of patients and imposing a heavy burden on families and society. The present work adopted a network pharmacology-based approach to provide new insights into the active compounds and therapeutic targets of Shuyu Capsule for the treatment of depression. Ninety-two avtive ingredients of Shuyu Capsule possessing favorable pharmacokinetic profiles and biological activities were selected,interacting 96 depression-related targets to provide potential synergistic therapeutic actions.Systematic analysis of the constructed networks revealed that these targets such as ESR1, PTGS2, NOS2 and SLC6A4 were mainly involved in prolactin signaling pathway, PI3K-Akt signaling pathway,serotonergic synapse and thyroid hormone signaling pathway.